Related Experiment Video
Updated: Feb 8, 2026

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication
Published on: October 30, 2021
A natural compound, aristoyagonine, is identified as a potent bromodomain inhibitor by mid-throughput screening
Young Hun Kim1, Minsung Kim2, Miyoun Yoo1
1Bio & Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon, 34114, Republic of Korea.
Abstract:
Bromodomain-containing protein 4 (Brd4) is known to play a key role in tumorigenesis. It binds acetylated histones to regulate the expression of numerous genes. Because of the importance of brd4 in tumorigenesis, much research has been undertaken to develop brd4 inhibitors with therapeutic potential. As a result, various scaffolds for bromodomain inhibitors have been identified. To discover new scaffolds, we performed mid-throughput screening using two different enzyme assays, alpha-screen and ELISA. We found a novel bromodomain inhibitor with a unique scaffold, aristoyagonine. This natural compound showed inhibitory activity in vitro and tumor growth inhibition in a Ty82-xenograft mouse model. In addition, we tested Brd4 inhibitors in gastric cancer cell lines, and found that aristoyagonine exerted cytotoxicity not only in I-BET-762-sensitive cancer cells, but also in I-BET-762-resistant cancer cells. This is the first paper to describe a natural compound as a Brd4 bromodomain inhibitor.
Insights
A novel natural compound, aristoyagonine, acts as a Bromodomain-containing protein 4 (Brd4) inhibitor. It effectively reduced tumor growth in mice and showed cytotoxicity in gastric cancer cells, including resistant types.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Bromodomain-containing protein 4 (Brd4) is a key regulator of gene expression implicated in tumorigenesis.
- Developing targeted therapies, such as Brd4 inhibitors, is crucial for cancer treatment.
- Identifying novel scaffolds for Brd4 inhibitors can overcome existing resistance mechanisms.
Purpose of the Study:
- To discover novel scaffolds for Bromodomain-containing protein 4 (Brd4) inhibitors.
- To evaluate the therapeutic potential of a newly identified natural compound, aristoyagonine, as a Brd4 inhibitor.
Main Methods:
- Mid-throughput screening using alpha-screen and ELISA enzyme assays to identify novel inhibitors.
- In vitro biochemical assays to confirm inhibitory activity.
- In vivo studies using a Ty82-xenograft mouse model to assess tumor growth inhibition.
- Cytotoxicity assays in gastric cancer cell lines, including those resistant to known inhibitors.
Main Results:
- A novel natural compound, aristoyagonine, was identified as a Brd4 bromodomain inhibitor with a unique scaffold.
- Aristoyagonine demonstrated significant in vitro inhibitory activity and reduced tumor growth in a xenograft mouse model.
- Aristoyagonine exhibited cytotoxicity against both I-BET-762-sensitive and I-BET-762-resistant gastric cancer cells.
Conclusions:
- Aristoyagonine represents the first described natural compound with Brd4 bromodomain inhibitory activity.
- This natural compound holds promise as a potential therapeutic agent for gastric cancer, including cases resistant to existing treatments.
- The unique scaffold of aristoyagonine opens new avenues for the development of next-generation Brd4 inhibitors.
Related Concept Videos
Molecules and Compounds
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
What is Natural Selection?
Classification of Elements and Compounds
Compounds are pure substances composed of two or more elements in fixed, definite proportions. Compounds are classified as ionic or molecular (covalent) based on the bonds...
Nature and Nurture
Organic Compounds

